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INTRODUCTION 
 
Chronic kidney disease is one of the most common diseases in practice 
known for its morbidity and mortality.1 
Chronic kidney disease (CKD) encompasses a spectrum of different 
pathophysiologic processes associated with abnormal kidney function, 
and a progressive decline in glomerular filtration rate (GFR). 2 
The varied etiology of chronic kidney disease are as follows:3 
Disease Proportion of ESRD 
 
Congenital and inherited   
 
5% 
Renal artery stenosis 
 
5% 
Hypertension 
 
5 – 25% 
Glomerular diseases  
 
10 – 20 % 
Diabetes mellitus 
 
20 -40% 
Systemic inflammatory diseases 
 
5% 
Unknown  
 
5 – 20 % 
2 
 
Glomerulonephritis was the most common cause of chronic kidney 
disease, not including diabetic nephropathy, followed by interstitial 
disease and benign arterionephrosclerosis. In patients with unidentified 
severe chronic kidney disease, renal biopsy provided an aetiological 
diagnosis.4 
Chronic kidney disease has been staged based on the GFR as follows:5 
Classification of Chronic Kidney Disease (CKD) 
 
Stage GFR, mL/min per 1.73 m2  
0 >90 With risk factors for CKD 
1 >90  With demonstrated kidney damage (e.g., persistent 
proteinuria, abnormal urine sediment, abnormal blood and 
urine chemistry, abnormal imaging studies)  
2 60–89 
3 30–59 
4 15–29 
5 <15 
 
 
3 
 
Adapted from US National Kidney Foundation Kidney Disease Quality 
Outcomes Initiative Classification ( American Journal of Kidney 
Disease) . 
The term chronic renal failure applies to the process of 
continuing significant irreversible reduction in nephron number, and 
typically corresponds to CKD stages 3–5. The term end-stage renal 
disease represents a stage of CKD where the accumulation of toxins, 
fluid, and electrolytes normally excreted by the kidneys results in the 
uremic syndrome.2 
                   The uremic syndrome and the disease state associated with 
advanced renal impairment involve more than renal excretory failure. 
A host of metabolic and endocrine functions normally undertaken by 
the kidneys are also impaired, and this results in anemia, malnutrition, 
and abnormal metabolism of carbohydrates, fats, and proteins. 
Furthermore, plasma levels of many hormones, including PTH, insulin, 
glucagon, sex hormones, and prolactin, change with renal failure as a 
result of urinary retention, decreased degradation, or abnormal 
regulation. Finally, progressive renal impairment is associated with 
worsening systemic inflammation. Elevated levels of C-reactive 
protein are detected along with other acute-phase reactants, while 
levels of so-called negative acute-phase reactants, such as albumin and 
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ferritin, decline with progressive renal impairment. Thus, renal 
impairment is important in the malnutrition-inflammation-
atherosclerosis/calcification syndrome, which contributes in turn to the 
acceleration of vascular disease and comorbidity associated with 
advanced renal disease. 
Glucose metabolism is impaired in CKD, as evidenced by a 
slowing of the rate at which blood glucose levels decline after a 
glucose load. Glucose intolerance can occur in chronic renal failure 
when GFR is less than 10–20 mL/min. Primarily, this is due to 
peripheral insulin resistance. Fasting glucose levels are usually normal 
or only slightly elevated. Therefore, patients can be either 
hyperglycemic or hypoglycemic depending on the predominant 
disturbance. Because the kidney contributes to insulin removal from 
the circulation, plasma levels of insulin are slightly to moderately 
elevated in most uremic patients, both in the fasting and postprandial 
states. Because of this diminished renal degradation of insulin, patients 
on insulin therapy may need progressive reduction in dose as their 
renal function worsens. Many hypoglycemic agents require dose 
reduction in renal failure, and some, such as metformin, are 
contraindicated when the GFR is less than half of normal. 
5 
 
There is increased prevalence of impaired glucose tolerance in 
chronic renal failure patients who are non diabetic patients, and at the 
background of this information this study was done. 
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REVIEW OF LITERATURE 
 
Chronic kidney disease in India 
Mani et al6 in a study in Chennai, South India, estimated a prevalence 
of chronic renal failure of 0.16 per cent in the community in 2003; 
applying the Modification in Diet in Renal Disease (MDRD) equation 
for GFR estimation in 2005, 0.86 per cent were found to have a GFR 
<80ml/min/1.73 [m.sup.2] . Agarwal and co-workers 7 arrived at an 
estimate of 0.78 per cent for CKD, in a community-based sample in 
New Delhi defined by an elevated serum creatinine >1.8 mg/dl.  
Estimates for the United States population extrapolated from the 
National Health and Nutrition Examination Survey (NHANES III) 8  
data place the prevalence of CKD stages 4 and 5 (severe decrease in 
GFR) and CKD stage 3 (moderate decrease in GFR) at 0.4 per cent . 
 However, such direct comparisons with Western populations are not 
valid, since the equivalent GFR for a serum creatinine of 1.8 mg/dl in 
Indians may place the individual anywhere between CKD stages 2 to 4 
depending upon gender and nutritional status. 
Modi and Jha 9  reported from an urban population in the city of 
Bhopal, that the crude and age-adjusted incidence rates of end stage 
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renal disease (ESRD) were 151 and 232 per million population, 
respectively. ESRD incidence rates lend themselves more easily to 
international comparisons as the diagnosis is less susceptible to 
inaccuracies. These estimates are roughly similar to the US 8. 
 
DISTURBANCES IN CARBOHYDRATE METABOLISM  IN 
CKD 
Disturbances in carbohydrate metabolism, especially glucose 
intolerance, are common in CKD patients, particularly in patients on 
dialysis10.One major factor behind the reduced glucose tolerance in 
uremia is an impaired sensitivity to insulin (insulin resistance, IR) in 
peripheral tissues, mainly in skeletal muscle. The most common 
manifestation of IR is glucose intolerance. However, in addition to 
abnormalities in carbohydrate metabolism, as has been pointed out,10 
the IR syndrome is accompanied by an elevation in non-esterified fatty 
acids, abnormalities in visceral fat metabolism, elevated uric acid, 
elevated hematocrit, endothelial dysfunction, and abnormalities in 
glucocorticoids. In addition, there appear to be differences in the 
phenotypic expression of the syndrome between men and women and 
associated abnormalities in fat distribution.10  Elevations in non-
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esterified fatty acids, in turn, appear to contribute to glucose 
intolerance, hypertension, and increased arteriosclerosis. 
GLUCOSE INTOLERANCE 
Impaired fasting glucose is defined as fasting glucose >110mg% 
and < 126mg% which favours early onset of microvascular 
complications namely diabetic nephropathy , retinopathy , neuropathy 
even in the absence of overt diabetes mellitus. 
 
Impaired glucose tolerance is defined as 2hours post glucose 
challenge blood glucose >140 mg % and  <200 mg%. Impaired glucose 
intolerance favours early onset of macrovascular complications like 
coronary artery disease , cerebrovascular accident , peripheral vascular 
disease even in the absence of overt diabetes mellitus. 
 
INSULIN RESISTANCE 
Several factors are  implicated in the pathogenesis of insulin 
resistance in chronic renal failure which include: uremic toxins, 
exercise tolerance, metabolic acidosis, secondary hyperparathyroidism, 
vitamin D deficiency etc 
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The characterization of IR in pre- dialysis patients dates back to 
classic studies from the late 1950s.11,12,13. Defronzo and colleagues,11 in 
experiments using the euglycemic insulin clamp technique. They 
demonstrated that in 17 chronically uremic and 36 control subjects, IR 
reflected tissue insensitivity to insulin rather than suppression of 
hepatic glucose production by physiologic hyperinsulinemia or 
abnormalities in insulin-mediated glucose uptake by the liver.  
 
Insulin resistance may have an important role in the 
development of atherosclerosis, which is the most common cause of 
morbidity and mortality in hemodialysis patients. [14,15,16]  
 
IR and concomitant hyperinsulinemia occur regardless of 
underlying etiology of the kidney disease.. Evidence suggests that 
reduced insulin production results from beta cell insensitivity to 
glucose rather than functional exhaustion of beta cells.(17)Calcium and 
phosphate disturbances, including vitamin D therapy, significantly 
reduces insulin resistance in uremia, suggesting a role for 
hyperparathyroidism. 
Factors implicated in the pathogenesis of insulin resistance in 
chronic renal failure are 
10 
 
1.UREMIC TOXINS: Hippurate and pseudouridine are specific for 
uremia and inhibit glucose utilization at concentrations found in sera of 
uremic subjects. Partially purified toxins from uremic sera, after 
hemodialysis therapy, ameliorate beta-cell response to hyperglycemia 
and increase tissue sensitivity to insulin. 
 
Possible Causes of Insulin Resistance in Patients with Chronic 
Kidney Disease 
Kidney related 
 Accumulation of nitrogenous wastes 
 Uric acid 
 Pseudo-uridine 
 NC-Asparagine 
Kidney unrelated 
 Resistin 
 Adiponectin 
 Pro-inflammatory cytokines (e.g., TNF-alpha) 
 Free fatty acids 
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2.EXERCISE INTOLERANCE: Exercise intolerance is common 
among hemodialysis patients, and also it can be the cause of insulin 
resistance. Moderate endurance training program improved both the 
exercise tolerance and insulin sensitivity in patients on hemodialysis.  
 
3.METABOLIC ACIDOSIS: Metabolic acidosis is frequent in uremia, 
but not in hemodialysis patients. Treatment of metabolic acidosis 
increases insulin sensitivity and insulin secretion, but significant 
degree of insulin resistance still exists in uremic patients.  
 
4.SECONDARY HYPERPARATHYROIDISM: After surgical 
correction of hyperparathyroidism, in hemodialysis patients, glucose 
tolerance and insulin secretion increase without significant changes in 
insulin sensitivity. Defect in insulin release attributable to reduced 
ATP content in the pancreatic islets induced partially by high 
intracellular calcium, secondary to augmented PTH-induced calcium 
entry into cells.  
 
5.VITAMIN D DEFICIENCY: Acute and chronic intravenous 1,25-
Dihydroxycholecalciferol therapy corrects insulin resistance in dialysis 
patients, in absence of PTH suppression. These results are consistent 
12 
 
with the hypothesis that 1,25(OH)2 D3 deficiency is a primary factor 
of insulin resistance.  
Dr Suleyman Turk et al Department of Nephrology, University 
Hospital, Selcuk University  evaluated the effect of calcitriol treatment 
on glucose intolerance in uraemia and found that 
blood glucose significantly decreased after calcitriol treatment at 0, 30, 
60, 90, and 120 min.These results seem to confirm that vitamin D 
influences pancreatic beta (β) cell secretion and suggest that calcitriol 
may improve glucose intolerance in uraemic haemodialysis patients. 
This effect of calcitriol is probably due to normalization of serum PTH 
and regulation of intracellular calcium concentration. 
 
6.ERYTHROPOETIN Deficiency:  Treatment with recombinant 
human erythropoietin (EPO) also appears to improve insulin 
sensitivity, although the mechanism is not well established. . 
ERYTHROPOIETIN THERAPY corrects insulin resistance  beside  
anaemia. 
 
Angiotensin-converting enzyme inhibitors have been shown to 
improve insulin resistance, hyperinsulinemia, and glucose intolerance 
in uremic patients.(18)  
13 
 
Insulin resistance has been postulated as an important factor in 
modulating the excess risk of cardiovascular disease. IR manifests with 
hyperinsulinemia, glucose intolerance, hyperglycemia, and 
dyslipidemia.(19) IR may also indirectly result in renal damage.[20 ] 
Several other possible factors have been implicated  . The impact of 
accumulating nitrogenous waste products in the context of a 
progressively uremic environment over time in a patient with CKD has 
been supported by several studies. Both renal replacement therapy and 
a low protein diet improve insulin resistance. Accumulation of uric 
acid in renal failure also appears to be associated with insulin 
resistance, although causality remains to be proven. Pseudouridine, a 
nucleotide that accumulates in patients with progressive kidney failure, 
has been observed in rats to reduce glucose utilization in muscles 
isolated. N-carbamoyl-L-asparagine has been observed to selectively 
reduce insulin-mediated glucose uptake in adipocytes.[95] N-carbamoyl-
L-asparagine, one of 15 carbamoylated amino acids, selectively 
reduced insulin-mediated glucose uptake in adipocytes. 
Carbamoylation of insulin also reduces its activity. 
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It is postulated that IR results in compensatory hyperinsulinism and 
that excessive insulin promotes the proliferation of renal cells and 
stimulates the production of other important growth factors such as 
insulin-like growth factor-1 and transforming growth factor beta.  
 
An article published in The Lancet, Volume 292, Issue 7572, 
Pages 798-801 states that malnutrition in chronic renal failure leads to 
increased growth hormone which causes insulin resistance producing 
impaired glucose tolerance.Insulin resistance and hyperglycemia adds 
on to the morbidity leading to dyslipidaemia , increasing risk for 
atherosclerosis. 
                                  
The uremic state described is attributable to the uremic toxins 
that may impair intracellular glucose utilization to produce hyper 
glycemia and cause insulin resistance. Non diabetic CKD patients 
usually have mildly elevated  blood glucose  levels and impaired 
glucose tolerance which does not require therapeutic reduction of 
blood glucose – S.shah, API TEXTBOOK OF MEDICINE 8th edition 
,2008,vol1,73721 
 
METABOLIC ACIDOSIS: Metabolic acidosis is frequent in 
uremia, but not in hemodialysis patients. Treatment of metabolic 
15 
 
acidosis increases insulin sensitivity and insulin secretion, but 
significant degree of insulin resistance still exists in uremic patients. 
 
 LIPID DISTURBANCES 
  Cardiovascular risk increases with each decrement in renal 
function. Lipoprotein composition with increased abundance of small 
dense LDL and HDL and reduced levels of more buoyant isoforms is 
similar to what is found in states of insulin resistance and in the 
metabolic syndrome (MS). In both cases, high triglyceride levels are 
associated with reduced HDL levels. Chronic kidney disease (CKD) 
associated with increasing insulin resistance results in decreased levels 
of apo A-I and apo A-II as a consequence of increased fractional 
catabolic rate (FCR), resulting from a predominance of small HDL 
particles. HDL maturation is impaired in CKD through decreased 
activity of lecithin:cholesterol acyltransferase (LCAT), and increased 
cholesterol ester transfer protein (CETP) activity in MS shuttles 
triglycerides back into HDL, thereby destabilizing it. Whether insulin 
resistance is entirely responsible for disorders of HDL metabolism in 
CKD, or whether the process is a result of unrelated pathophysiology, 
is currently unknown.22 
16 
 
Nonphysiologic concentrations of urea have been reported to 
increase levels of ROS. End-stage renal disease (ESRD) patients have 
increased levels of oxidative stress , and intracellular ROS induced by 
hyperglycemia increase protein modification by O-linked β-N-
acetylglucosamine (O-GlcNAc) . Increased modification of key 
signaling molecules by O-GlcNAc was recently shown to cause 
reduced insulin signal transduction . Insulin resistance is a well-
documented feature of ESRD, and the rate of death among 
hemodialysis patients is greater in those with more severe insulin 
resistance . The insulin resistance present in ESRD appears to start 
much earlier in the course of chronic kidney disease, when renal failure 
is subclinical . Although the cause of insulin resistance in chronic renal 
disease is unknown , several abnormalities associated with ESRD 
might interfere with insulin signaling. The concentrations of urea 
associated with CRF might drive insulin resistance by increasing ROS 
production, thereby increasing modification of insulin signaling 
molecules by O-GlcNAc. 
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PROTEINURIA AND GLUCOSE TOLERANCE  
 
In a study conducted in Australia  , The Aus Diab Kidney Study, 
11,247adults of  more than 25 years of age  were screened between 
April 1999 and December 2000. Albuminuria was determined by urine 
albumin:creatinine ratio with normal 3.4 mg/mmol, microalbuminuria 
= 3.4 to 34 mg/mmol, and macroalbuminuria 34 mg/mmol. 
Proteinuria was determined by urine  protein:creatinine ratio (mg/mg) 
with abnormal proteinuria 0.2 mg/mg, which approximates 250 
mg/24-hour excretion 
 
AUSDIAB24 results showed that 7.2% of adult Australians in the 
community have diabetes. A portion (3.6%) knew they had diabetes, 
and 3.6% were undiagnosed. A percentage of adults (16.1%) had 
impaired glucose metabolism, 60% were overweight or obese, 61% 
had high cholesterol, and 29% had elevated blood pressure, with only 
14% on treatment 
 
The effect of hypertension and glucose tolerance on the 
prevalence of albuminuria demonstrated an enhancing effect. With 
increasing degrees of glucose intolerance there were increasing 
18 
 
amounts of albuminuria. However, when the effect of hypertension 
was also taken into account, microalbuminuria was increased at each 
degree of glucose intolerance in an incremental fashion, with 25.4% of 
people with diabetes mellitus and hypertension having albuminuria 25 
COMPARISON OF HYPERTENSION AND GLUCOSE TOLERANCE  
 
Elevated urea in chronic renal failure (CRF) is considered to 
have negligible toxicity because Johnson et al. found in 1972 that in 
patients with far-advanced renal failure, blood urea concentrations of 
less than 50 mM (blood urea nitrogen [BUN] of 140 mg/dl) were well 
tolerated when blood urea concentration was maintained by adding 
urea to the dialysate solution  and 30 years later, the HEMO study 
19 
 
showed that increasing urea reduction rate from 66% to 75% did not 
alter survival in patients with an increased dialysis dose. However, 
more recent data have demonstrated that survival of patients on daily 
hemodialysis is 2- to 3-fold greater than that of patients dialyzed less 
frequently. The observation that in an animal model of CRF-
accelerated atherosclerosis, plasma urea was the only significant 
predictor of aortic plaque area fraction suggested to us that the high 
levels of urea found in chronic dialysis patients might play an 
important role in accelerated atherosclerosis in this group of patients.  
Insulin resistance per se contributes to micro and macrovascular 
complications adding on to the morbidity of chronic kidney disease. 
Impaired fasting glucose is defined as fasting glucose >110mg% 
and <126mg% which favours early onset of microvascular 
complications namely diabetic nephropathy , retinopathy , neuropathy 
even in the absence of overt diabetes mellitus. 
Impaired glucose tolerance is defined as 2hours post glucose 
challenge blood glucose >140 mg % and <200 mg%. Impaired glucose 
tolerance favours early onset of macrovascular complications like 
coronary artery disease , cerebrovascular accident , peripheral vascular 
disease even in the absence of overt diabetes mellitus. 
20 
 
INSULIN RESISTANCE AND METABOLIC SYNDROME 
Features of insulin resistance metabolic syndrome or syndrome X: 
• Hyperinsulinaemia.  
• Type II diabetes or impaired glucose tolerance. 
• Hypertension. 
• Low HDL and elevated triglycerides. 
• Central obesity. 
• Microalbuminuria. 
• Increase fibrinogen. 
• Increased plasminogen activator inhibitor 1. 
• Elevated plasma uric acid. 
• Increased sympathetic neural activity.  
 
This is strongly associated with atherosclerosis and other 
macrovascular complications. 
An article published in The Lancet, Volume 292, Issue 7572, Pages 
798-801 states that malnutrition in chronic renal failure leads to 
increased growth hormone which causes insulin resistance producing 
impaired glucose tolerance.Insulin resistance and hyperglycemia adds 
21 
 
on to the morbidity leading to dyslipidaemia , increasing risk for 
atherosclerosis.  
 It s clear from the above discussion that there a wide array of 
metabolic derangements in chronic kidney disease and some of them 
contributing to insulin resistance leading to glucose intolerance which 
has its own detrimental effect on the existing pathology. 
          This study deals with the metabolic disturbance in glucose in 
chronic kidney disease patient and whether it has any bearing on lipid 
profile hypertension and severity of renal failure. 
           This study also takes into account whether oral glucose 
tolerance test has to be done as a routine investigation in chronic 
kidney disease patients adding to the battery of investigations. This 
study helps to analyse whether oral glucose tolerance test has any 
added advantage over the existing list of investigations in chronic 
kidney disease patients. 
 
REVIEW OF ARTICLES 
In a study at Copenhagen on, Pre-diabetes and arterial stiffness in 
uraemic patients  found that   of  the 66  uraemic patients (41%) had 
pre-diabetes (IFG+IGT), and 39 had normal glucose tolerance. The 
uraemic patients were more insulin resistant with lower insulin 
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sensitivity index compared to healthy controls (6.1 ± 3 vs. 15 ± 7, P < 
0.0001) but with no difference between patients with and without pre-
diabetes. HbA1c and fasting plasma glucose was comparable in 
uraemic patients with and without pre-diabetes. In conclusion, a high 
prevalence of pre-diabetes, impaired insulin resistance, increased 
arterial stiffness of aorta as well as impaired augmentation index and 
vasodilatation was demonstrated in uraemic patients prior to kidney 
transplantation. Increased arterial stiffness of aorta and augmentation 
index were independently associated with age and blood pressure26 
 A  study on  Susceptibility to Hyperglycemia in Patients with 
Chronic Kidney Disease by, Walid Shehab-Eldin et al27 ,showed that 
,the prevalence of pre- diabetes was 40 percent . They proved that 
,increased IR, rather than β-cell dysfunction, was the primary 
mechanism of pre- diabetes in CKD patients 27 
In another  study by Kobayashi S et al ,they studied 39 subjects 
and using the hyperinsulinemic euglycemic glucose clamp technique 
was used to examine insulin sensitivity in patients without diabetes (n 
= 29) with different stages of renal function and study the metabolic 
abnormalities, such as apolipoprotein (Apo) profile or acidosis, 
associated with insulin resistance in patients with CKD and they found 
that, insulin resistance correlated linearly with decline in renal 
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function. Independent variables related to insulin resistance were 
bicarbonate and Apo A-/B levels in patients with CKD28 . In yet another  
study from Department of Internal Medicine, University of Missouri-
Columbia on  the Relationship between Hyperinsulinemia, 
Hypertension and Progressive Renal Disease  , found that  impaired 
glucose tolerance and hypertension are important contributors to 
ESRD. they also found out that Obesity, especially the visceral type, is 
associated with peripheral resistance to insulin actions and 
hyperinsulinemia, which predisposes to development of diabetes. A 
common genetic predisposition to insulin resistance and hypertension 
and the coexistence of these two disorders predisposes to premature 
atherosclerosis.  A constellation of metabolic and cardiovascular 
derangements, which also includes dyslipidemia, dysglycemia, 
endothelial dysfunction, fibrinolytic and inflammatory abnormalities, 
left ventricular hypertrophy, microalbuminuria, and increased 
oxidative stress, is referred to as the cardiometabolic syndrome. The 
components of this syndrome, individually and interdependently, 
substantially increase the risk of renal disease, cardiovascular disease 
(CVD) and mortality. Similar findings and cardiorenal risk factors can 
occur in subjects with android obesity without excess body weight. 29 
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In a study at the Tulane University School of Medicine  New 
Orleans, Louisiana  on Insulin Resistance and Risk of Chronic Kidney 
Disease in Nondiabetic  Adults identified a strong, positive, significant, 
and dose-response relationship among insulin resistance, insulin level, 
and risk of CKD among nondiabetic participants. This relationship was 
independent of age, gender, race, and other potential risk factors for 
CKD, such as BP, obesity, total cholesterol, education, physical 
activity, cigarette smoking, NSAID use, and alcohol  
Consumption. In their study, a HbA1c level greater than or equal to 
5.7% was associated with an elevated risk of CKD. These findings 
support the notion that intensive glycemic control in diabetics as well 
as a reduction of glycemic level in persons with an impaired 
fasting glucose may be important strategies for primary prevention of 
CKD and slowing the progression of CKD. 30 
 
A  notable study done  at the , University Magna-Graecia of 
Catanzaro, Catanzaro, Italy on  One-Hour Postload Plasma Glucose 
Levels showed a link between postload hyperglycemia and kidney 
dysfunction, showed that , individuals with 1hPG ≥155 mg/dl had a 
worse cardiometabolic risk profile, exhibiting significantly higher body 
mass index, BP, triglycerides, and fasting insulin levels and lower 
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HDL, IGF-1 levels, and insulin sensitivity, than individuals with 1hPG 
<155 mg/dl. The Estimated GFR was significantly lower in individuals 
with 1hPG ≥155 mg/dl.  These results showing a link between postload 
hyperglycemia and kidney dysfunction may have clinical implications. 
Lifestyle changes and pharmacologic treatment in individuals who are 
high risk for type 2 diabetes have been demonstrated to be effective in 
reducing the incidence of type 2 diabetes and cardiovascular risk 
factors. This suggests   that performing OGTT with measurement of 
1hPG levels may be useful to identify individuals who have NGT and 
in whom it would be important to measure renal function in addition to 
risk factors for CVD, because they could benefit from lifestyle change 
interventions and, possibly, pharmacotherapy to prevent or delay 
clinical adverse outcomes31 
 
In another study  on Insulin resistance and pancreatic beta-cell 
function in patients with hypertensive kidney disease, at Nara Medical 
University, Nara, Japan, HKD with moderate to severe renal 
dysfunction is associated with insulin resistance. Approximately  40% 
of HKD subjects were in an insulin-resistant state: only <10% of HTN 
subjects and ׽10–30% of CKD-NT subjects were insulin resistant.32 
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Another  study by Argani et al, showed that  significant linear 
correlation was observed with body mass index and IGT only in 
hemodialysis patients. Glucose tolerance also had a significant 
correlation with triglyceride levels , in hemodialysis patients Also ,the 
glucose tolerance had significant relationship with higher serum 
cholesterol levels only in the renal transplant recipients.33 
  
LIPID ABNORMALITIES  
Hyperlipidemia and Long-Term Outcomes in 
Nondiabetic Chronic Kidney Disease showed , a higher level of serum 
triglycerides, fibrinogen, total homocyst(e)ine and proteinuria, and a 
lower level of serum high-density lipoprotein in the ESRD(+) group 
than in the ESRD(−) group. . These results suggest a limited role for 
dyslipidaemia in the progression of  chronic renal disease to dialysis in 
CRF patients, in contrast with the powerful influence of proteinuria, 
baseline creatinine clearance and nephropathy type in predicting this 
progression. 
 
There was no association of TG, HDL-C, and NHDL-C as 
continuous variables with all-cause or CVD mortality  . There was a 
significant inverse association between HDL-C and kidneyfailure, 
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hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic 
Kidney Disease. 34 
In a study by  Donald S. Silverberg et al on the effect of 
correction of anaemia in diabetics and non‐diabetics with chronic renal 
failure ,by subcutaneous erythropoietin and intravenous iron, that the 
correction of the mild anaemia that was found in diabetics and 
non‐diabetics with resistant CHF and mild to moderate chronic renal 
failure improved the cardiac function and patient functional status, 
stabilized the renal function and markedly reduced the need for 
hospitalization. 35 
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AIMS AND OBJECTIVES 
 
AIM : 
To find out the  prevalence of impaired glucose tolerance in non 
diabetic chronic kidney disease patients and to analyse  its relation  
with other comorbidities of chronic kidney disease. 
 
Objective: 
1.To find out the prevalence  of impaired glucose tolerance in patients 
with non diabetic chronic kidney disease. 
2.To study its significance in relation to the severity of renal failure.  
3.To study its correlation with other comorbidities like dyslipidemia, 
obesity , proteinuria,etc. 
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MATERIALS AND METHODS 
Setting   : Department of Medicine,  
Government Rajaji Hospital. 
Design   : Descriptive study. 
Period of study  :  July 2010 To December 2010 
Ethical approval  :  Obtained from ethical committee headed by 
Dean,  Government Rajaji Hospital, Madurai. 
Consent   : Informed consent  obtained from all patients 
Statistical  
software   : SPSS  version 17.0 
 
Study population: OP and IP patients in Medicine and Nephrology 
i)Case: 
• Inclusion criteria: 
             Non diabetic chronic kidney disease patients. 
• Exclusion criteria: 
           1.Those not giving consent. 
    2.Other chronic ailment. 
  3.Patients with urinary tract infections. 
  4.Bed ridden, terminally ill patients. 
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5.Patients on drugs altering the glycemic status like 
steroids phenytoin etc 
 ii.Control: 
• Inclusion criteria: 
           Non diabetic healthy patients. 
• Exclusion criteria: 
          1.Those not giving consent. 
2.Other chronic ailment or on treatment with drugs 
producing   hyperglycaemia. 
  iii.Case definition: 
 Non diabetic chronic kidney disease patients Æ 
Pathological abnormalities or markers of damage 
including abnormalities in blood or urine tests or imaging 
studies(USG Abdomen) or GFR < 60ml/min/ 1.73 sq m 
for 3 months. 
 
Sample size:140 
Case 90 , control 50. 
In this study 90 patients were studied , and 50 age and sex  matched 
controls were taken. An informed consent was obtained from the 
patient, following which a meticulous history of the patient with regard 
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to CKD was taken,especially the presence of uremic symptoms , 
duration of CKD, Hypertension , drug history ,duration of treatment , 
intake of any steroids or other medications that could alter the 
glycemic status was also taken. History of  other co-morbidities were 
also recorded. 
The vital data especially the systolic BP and pulse pressure were 
carefully recorded, the fundus was examined to rule out cases with 
diabetic  retinopathy. Patients with diabetic retinopathy were excluded 
from the study. In the general examination we looked especially for 
pallor, signs of failure ,puffiness of face, any markers of insulin 
resistance were noted. Anthropometric measurements were also taken 
inorder to  calculate the BMI.  A careful examination of all the systems 
were also done., 
Following examination a battery a investigations were done. All 
patients underwent the following blood investigations including blood 
sugar, urea, serum creatinine, Fasting lipid profile etc.  Few urine 
investigations were also done which included ,urine albumin using heat 
coagulation test, urine Spot PCR, deposits were done . Those patients 
with Urinary tract infections were excluded from the study.  
Thereafter eGFR  was calculated from serum creatinine values using 
1) Cockroft Gault equation 5 
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Creatinine      (140-age) x body weight (kg) 
Clearance =      x 0.85 (for women) 
     72 x S.Creat  (mg/dl)  
2)    MDRD formula5 
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0.203 
 Multiply by 0.742 for women,  Multiply by 1.21 for African 
Americans. 
NKF-KDOQI staging of CKD was applied using MDRD formula and 
stage of CKD is determined. Once this was done, all the patients were 
subjected to  a standard OGTT(  oral glucose tolerance test) 
 
STANDARD OGTT(WHO) 
Preparation 
The patient is instructed not to restrict carbohydrate intake for atleast   
4 days  before the test. The test should not be done during an illness, as 
results may not reflect the patient's glucose metabolism when healthy. 
A full adult dose should not be given to a person weighing less than 
43 kg (94 lb), or exaggerated glucoses may produce a false 
positive result. The OGTT was performed in the morning as glucose 
tolerance can exhibit a diurnal rhythm with a significant decrease in the 
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afternoon. The patient is instructed to fast (water is allowed) for 8–12 
hours prior to the tests. 
Procedure 
1. A zero time (baseline) blood sample is drawn. 
2. The patient is then given a measured dose (below) of glucose 
solution to drink within a 5 minute time frame. 
3. Blood is drawn at intervals for measurement of  blood glucose 
levels .( blood was drawn at  1st hour and 2nd hour.) 
Dose of glucose . 
As in the WHO recommendation is 75g oral dose in all adults. 
Interpretation of OGTT results 
Fasting plasma glucose (measured before the OGTT begins) should be 
below 6.1 mmol/l (110 mg/dl). Fasting levels between 6.1 and 
7.0 mmol/l (110 and 125 mg/dl) are borderline ("impaired fasting 
glycaemia"), and fasting levels are at or above 7.0 mmol/l (126 mg/dl) 
are diagnostic of diabetes. 
The 2 hour OGTT glucose level should be below 7.8 mmol/l 
(140 mg/dl). Levels between this and 11.1 mmol/l (200 mg/dl) indicate 
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"impaired glucose tolerance"(IGT). Glucose levels above 11.1 mmol/l 
(200 mg/dl) at 2 hours confirms a diagnosis of diabetes. 
1999 WHO Diabetes criteria - Interpretation of Oral Glucose 
Tolerance Test
Glucose 
levels NORMAL 
impaired  fasting 
glycaemia 
(IFG) 
impaired 
glucose 
tolerance 
(IGT) 
Diabetes 
Mellitus 
(DM) 
Venous 
Plasma 
Fasting 2hrs Fasting 2hrs Fasting 2hrs Fasting 2hrs 
(mmol/l) <6.1 <7.8 > 6.1 & <7.0 <7.8 <7.0 >7.8 >7.0 >11.1
(mg/dl) <110 <140 >110& <126 <140 <126 >140 >126 >200
All these tests were done in both the cases and the controls. All 
these patients were reviewed. All investigations reports were entered in 
the proforma, and  tabulated in the excel spreadsheet. 
According to the calculated GFR, patients were divided into 
stage 1 to 5 CKD. Thereafter each of the parameters were compared 
within the CKD groups and with the controls 
All the datas were analysed using the SPSS software and a 
conclusion was arrived. The various statistical tools that were used 
were the chi-square test, the mean and standard deviation and the 
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independent sample T-test. The p value was obtained and then the 
parameters were said  to be significant or not depending on the p – 
value. Graphs were made with these conclusions using the excel and 
the SPSS  software. 
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RESULTS AND ANALYSIS 
TABLE 1 :COMPARISION OF BASELINE DATA 
Character Case n% (90) Control n%(50) 
1.Age    
<30y 14    (15.6) 6     (12) 
30 to 40 22    (24.4) 14   (28) 
40 to 50 18    (20) 11   (22) 
50 to 60 32    (35.6) 16   (32) 
60 to 70 4      (4.4) 3     (06) 
2.Sex   
Male  51    (56.7) 29   (58) 
Female 39    (43.3) 21   (42) 
3.CRF stage   
II 16    (14)  
III 11    (21)  
IV 30    (29)  
V 33    (36)  
4.BMI   
<18.5 underweight 14 (15.5) 10 (20) 
18.5 – 24.9 normal 60 (66.6) 22 (44) 
25 – 29.9 overweight 14 (15.5) 15 (30) 
>30 obese 2  (2.2) 3 (6) 
5.Prehypertension 57 (63.3) 0 
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6.Serum cholesterol   
<200 51 (56.6) 33 (66) 
200 – 250 26 (28.8) 17 (34) 
250 – 300 8 (8.8) 0 
>300 5 (5.5) 0 
7.serum triglyceride   
<150 66 (73.3) 18 (36) 
150 – 200 5   (5.5) 22 (44) 
200 – 250 12 (13.3) 10 (20) 
>250 7  ( 7.7) 0 
8.urine spot PCR   
<0.3 3   (3.3) 50 (100) 
0.3 to 1.0 54 (60)  
1.0 to 2.0 29 (32.2)  
>2 4   (4.4)  
9.Urine albumin   
Nil 0 50 (100) 
1+ 53 (58.8)  
2+ 15 (16.6)  
3+ 22 (24.4)  
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The above table shows the comparison of baseline data between 
the two study groups. This shows that, the groups are comparable with 
respect to age, sex , lipid profile and body mass index. 
Figure 1, represents the age and sex distribution among the study 
groups. Figure 2 shows the stages of chronic kidney disease in the 
study population. 
Figure 2, shows that , the major portion of the cases belonged to 
the stage 5 CKD,(38%) followed by 29,21,and 14% respectively in 
stages 4,3 and 2. 
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AGE DISTRIBUTION IN CASES  AND CONTROLS 
 
Figure 3 shows, a comparison of the age distribution in the cases 
and controls. The lowest age in the CKD group was 28, and in the  
control group was 26 ,and the highest was 67 and 68, respectively.  
The maximum number of cases in either groups  fall into the 51-60 age 
group in either groups.  The  percentage wise distribution  of the age 
was 12,28,22,32,6 in the age groups of <30,31-40,41-50,51-60,and 61-
70 respectively. Similarly  in the  corresponding age groups , controls 
were 15.6,24.4,20,35.6,4.4 respectively.  
This shows a similarity in the age distribution among cases and 
controls. 
  
SEX DISTRIBUTION IN CASES AND CONTROLS 
Figure 4, shows the sex distribution among cases and controls. There 
are 43.3% females in case group and  42% in the control group . 
Among the males it is 56.7% and 58 % in cases and controls 
respectively.  
This shows  that  this study has a sex matched control group . 
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TABLE :2: COMPARISON OF 2 HR GTT TO STAGE OF CKD 
 
 
 
GTT-2Hr 
Total < 140  >=140  
CKD Stage  2  Count  15  1  16  
Percent  25.4%  3.2%  17.8%  
3  Count  9  2  11  
Percent  15.3%  6.5%  12.2%  
4  Count  17  13  30  
Percent  28.8%  41.9%  33.3%  
5  Count  18  15  33  
Percent  30.5%  48.4%  36.7%  
Total  Count  59  31  90  
Percent  100.0% 100.0%  100.0%  
Chi square test P value .021   
  
This table shows a comparison of CKD stages to, 2hour glucose 
tolerance values. Of all the CKD patients, there was a statistically  
significant  increase in the percentage of patients having IGT( i.e:>140) 
after a 2 hour glucose load, as the stage of CKD advances.(p=0.021). 
When there was only 3.2% and 6.5% cases with IGT in  stages 2 and 3 
CKD there was  a significant rise to 41.9% and 48.4% respectively in 
CKD  stages  4 and 5 respectively. 
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TABLE: 3 COMPARISON OF ONE HOUR GLUCOSE 
TOLERANCE TO  CKD STAGE 
                                     
GTT_1h 
Total  <= 155  >155  
CKDStage  Stage 3  Count  8  3  11  
Percent  72.7%  27.3% 100.0% 
Stage 4  Count  20  10  30  
Percent  66.7%  33.3% 100.0% 
Stage 5  Count  13  20  33  
Percent  39.4%  60.6% 100.0% 
Total  Count  41  33  74  
Percent  55.4%  44.6% 100.0% 
Chi-square test P value 0.43   
  
This table shows a comparison of one hour post glucose load  blood 
sugar > 155 to the different CKD stages. There is a  steady increase  in  
the blood glucose  more than 155  as the stage of CKD  progresses. In 
stage 3 CKD when there were only 27 % in stage 3 CKD that 
progressively increased to 33.3% and 60.6% respectively in stages 4 
and 5. 
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TABLE 4: RELATIONSHIP BETWEEN TOTAL  
CHOLESTEROL  AND GLUCOSE INTOLERANCE IN CKD  
PATIENTS. 
Serum 
cholesterol 
(mg%) 
No of CKD 
patients 
Impaired 
glucose 
tolerance 
Percentage 
<200 
 
51 21 41.1 
200 – 250 
 
26 3 11.5 
250 – 300 
 
8 4 50 
>300 
 
5 3 60 
The above table shows the relation between serum cholesterol and 
glucose intolerance in chronic kidney disease patients which shows 
that with increasing serum cholesterol, there is impaired glucose 
tolerance. 
Figure 7 shows the relationship between serum cholesterol and glucose 
intolerance in chronic kidney disease patients. 
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TABLE 5: RELATIONSHIP BETWEEN SERUM 
TRIGLYCERIDE AND GLUCOSE INTOLERANCE IN 
CHRONIC KIDNEY DISEASE PATIENTS. 
Serum 
triglyceride 
(mg%) 
 
No of CKD 
patients 
Impaired 
glucose 
tolerance 
Percentage 
<150 66 24 36% 
150 – 200 5 3 60% 
200 – 250 12 0 0 
>250 7 4 57% 
The above table shows the relation between serum triglyceride and 
glucose intolerance in chronic kidney disease patients which shows 
that with serum triglyceride > 150mg %  there is increase in impaired 
glucose tolerance. 
Figure 8 shows the relationship between serum triglyceride and 
glucose intolerance in chronic kidney disease patients 
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TABLE 6 : HDL AND IGT 
 
HDL  (mg %) 
 
Total Impaired 
glucose 
tolerance 
Percentage 
<40  
 
4 4 100 
40 – 45 
 
80 26 32.5 
>45 
 
6 1 16.6 
 
This table shows, the relationship between IGT and HDL values.             
It shows that, patients with IGT had lower levels of HDL. 
 
Figure 9 shows the relationship between, IGT and HDL. 
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TABLE 7 :  BMI  AND  IGT 
Body mass index 
 
No of CKD 
patient 
Impaired glucose 
tolerance 
Percentage 
<18.5 14 5 35.7 
18.5 – 24.9 60 19 31.6 
25 – 29.9  14 5 35.7 
>30 2 1 50 
The above table shows the relation between body mass index and 
impaired glucose tolerance which does not show any significant 
relation between body mass index and glucose tolerance. 
Figure 10 shows the relation between body mass index and glucose 
tolerance. 
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TABLE  8 : ALBUMINURIA  AND IGT 
 
Urine albumin IGT% 
1+ 15% 
2+ 16% 
3+ 69% 
 
TABLE 9 :  
Albuminuria 
 
Total Impaired 
glucose 
tolerance 
Percentage 
1+ 
 
53 7 13.2 
2+ 
 
15 4 26.6 
3+ 
 
22 20 90.9 
 
The above  tables show relationship between , albuminuria and IGT. 
With worsening  of albuminuria, the percentage of patients with IGT 
also increases. 
Figures  show the relationship between albuminuria and IGT. 
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TABLE 10 : 
Spot PCR 
 
Total Impaired 
glucose 
tolerance 
Percentage 
<0.3 
 
3 1 33.3 
0.3 – 1 
 
49 7 14.28 
1 – 2 
 
30 16 53.3 
>2 
 
8 7 87.5 
 
 
This table shows the relationship between spot PCR and IGT. It shows 
that with worsening proteinuria  glucose tolerance  is also impaired. 
 
Figure  13  shows the comparison of spot PCR to IGT. 
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TABLE 11: SEX AND IMPAIRED GLUCOSE TOLERANCE 
 
Age 
 
Total IGT Percentage 
<  30 years 
 
14 3 21.4 
31 to 40 years 
 
22 7 31.81 
41 to 50 years 
 
18 10 55.5 
51 to 60 years 
 
32 9 28.12 
>60 years 
 
4 1 25 
 
This table shows the sex  distribution of IGT  among CKD  patients. 
The prevalence of IGT  is comparable between the sexes. 
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DISCUSSION 
 
Disturbances in carbohydrate metabolism, especially glucose 
intolerance, is common in CKD patients, particularly in patients on 
dialysis.  One major factor for the reduced glucose tolerance in uremia 
is an impaired sensitivity to insulin (insulin resistance, IR) in 
peripheral tissues, mainly in skeletal muscle. Glucose metabolism is 
impaired in CKD, as evidenced by a slowing of the rate at which blood 
glucose levels decline after a glucose load. The burden of CKD is 
increasing worldwide and it has doubled over the past 15 yrs. 
 
In this study  titled a study of glucose tolerance in non – diabetic 
CKD patients , we studied  a total of 140  patients 90 belonging to the  
study group and 50 belonging to the control group. 
 
AGE 
For the 90 patients we studied, we had obtained 50 age matched 
controls. In our  study the  lowest age among patients in the cases 
group was 28 and in the  control group was 26 ,and the highest was 67 
and 68  respectively.  The maximum number of patients observed were 
in the age groups  of 31 to 40 and 51-60 age group. Our study 
correlates well with the findings of Indian literature. In a  study by rao 
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et al in 1998, observed that the mean age of CKD patients was  38 
which again correlates with our study.38  
 
SEX 
The sex distribution in our study was,  43.3%  females in patients 
group and  42% in the control group and  males contributed about 
56.7% and 58 % in patients and controls respectively. It was sex 
matched with the control group. This shows that there was a slight 
male preponderance . This is again in concordance with a study by 
madhumathi et al 39conducted at CMC Vellore which showed that there 
was no significant change in the sex ratio but for a slight male 
preponderance. 
 
CKD STAGE 
In this study , 36% of the patients were in stage 5 CKD, 29% patients 
were in stage 4 CKD ,and 21%,14% in stages 3 and 2 respectively, 
suggesting that most of our patients seek medical help at stage 5 CKD 
(1/3). 
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IGT IN CKD 
In our study, there were no cases with IFG (impaired fasting 
glucose). In the GTT done  2 hours after a glucose load when  there 
was only  3.2% and 6.5% cases with IGT in  stages 2 and 3 CKD, there 
was  a significant rise to 41.9% and 48.4% respectively in CKD  stages  
4 and 5 respectively, indicating that as the CKD stage progresses there 
is a progressive increase in the glucose intolerance which was 
statistically significant.(p=0.021). This was in concordance with a 
study on  Susceptibility to Hyperglycemia in Patients with Chronic 
Kidney Disease by Walid Shehab-Eldin et al27 ,which studied  the 
prevalence of pre-diabetes in CKD patients and determine the 
contribution of insulin resistance (IR) versus β-cell dysfunction in 
patients with CKD . IR was assessed by homeostasis model assessment 
of insulin resistance (HOMA-IR) and β-cell function was assessed by 
proinsulin/insulin ratio and β-cell percent . The prevalence of PDM 
was 40 percent. He concluded that, increased IR, rather than β-cell 
dysfunction, is the primary mechanism of PDM in CKD patients. 
In a study at Copenhagen26 on , pre-diabetes and arterial stiffness 
in uraemic patients  found that   of  the 66  uraemic patients 41%, had 
pre-diabetes (IFG+IGT), and 39 had normal glucose tolerance. The 
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uremic patients were more insulin resistant with lower insulin 
sensitivity index compared to healthy controls ( P < 0.0001), but with 
no difference between patients with and without pre-diabetes. HbA1c 
and fasting plasma glucose were comparable in uraemic patients with 
and without pre-diabetes. 
In yet another  study by Kobayashi S et al28 ,they studied 39 
subjects and using the hyperinsulinemic euglycemic glucose clamp 
technique was used to examine insulin sensitivity in patients without 
diabetes (n = 29) with different stages of  CKD, and  found that, insulin 
resistance correlated linearly with decline in renal function.  
Independent variables related to insulin resistance were bicarbonate 
and Apo A-1/B levels in patients with CKD. 
Thus it may be noted that as the renal function declines , the 
glucose tolerance becomes more impaired and the predominant 
mechanism being insulin resistance. 
ONE HOUR POST-PRANDIAL GLUCOSE AND  CKD 
In our study, the prevalence of patients with one hour post glucose load 
showed ,there was a  steady increase  in  the blood glucose  more than 
155, as the stage of CKD  progresses. In stage 3 CKD,   when there 
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were only 27 % patients with IGT, it progressively increased to 33.3% 
in stage 4  and 60.5%  in stage 5 CKD. 
These results were comparable to a  notable study done  at the , 
University Magna-Græcia of Catanzaro, Catanzaro, Italy31, showed a 
link between post load hyperglycemia and kidney dysfunction . 
Individuals with 1hPG ≥155 mg/dl had a worse cardiometabolic risk 
profile, exhibiting significantly higher body mass index, BP, 
triglycerides, and fasting insulin levels and lower HDL, IGF-1 levels, 
and insulin sensitivity, than individuals with 1hPG <155 mg/dl. The 
Estimated GFR was significantly lower in individuals with 1hPG ≥155 
mg/dl. These results showing a link between post load hyperglycemia 
and kidney dysfunction may have clinical implications. This suggests   
that performing OGTT with measurement of 1hPG levels may be useful 
to identify individuals who have NGT and in whom it would be 
important to measure renal function in addition to risk factors for CVD, 
because they could benefit from lifestyle change interventions and, 
possibly, pharmacotherapy to prevent or delay clinically adverse 
outcomes. 
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IGT and Proteinuria: 
In the comparison between IGT and proteinuria, 69% of the 
cases with IGT had, 3+ albuminuria, whereas, only 16% cases had 2+ 
and 15% had 1+ albuminuria.  
This is correlating with a study by Nelson et al earlier this year, 
where in they found that, subjects with imparied glucose tolerance 
were found to have a higher prevalance of abnormal albuminuria than 
those with normal glucose tolerance. 
In a study by of Edward Kessle et al41, found that , glucose 
tolerance worsens in  individuals excreting 1.0 g or more proteinuria/ 
day and this can lead on to  prediabetic state   or have chemical 
diabetes. The increased proteinuria could reflect glomerular 
nephrosclerosis. 
 
A role for insulin resistance in the pathogenesis of 
microalbuminuria has been suggested, because the severity of IR 
appears to correlate with the severity of microalbuminuria.20. Indeed, 
data suggests that  this endothelial-dependent vasodilatation is 
abnormal in microalbuminurics  and this is linked with insulin 
resistance - Brenner  nephrology 8 th edition2 
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Proteinuria is an independent marker for the progression of 
CKD. When managing patients with CKD, we aim to retard, and—if 
possible—reverse the progression of renal disease, and also to prevent 
CKD-related complications such as bone and cardiovascular diseases. 
In a recent study by Alessia Fornoni et al42,  insulin resistance 
correlates with the onset and severity of albuminuria. This correlation 
has also been found in normotensive persons who do not have diabetes, 
suggesting that insulin resistance per se may cause albuminuria. This 
may be due to podocyte dysfunction.  
 
HDL CHOLESTEROL AND IGT 
An independent sample T-test was done on the samples and 
control groups  and the test showed that the mean HDL value in the 
study group was 41.61 with a standard deviation of 1.852. whereas in 
the control group the mean HDL value was 46.8 with a standard 
deviation of 2.648. The  HDL values ranged from 38 to 45 in the study 
group and 40 to 52 in the control group . 
 
This shows a significant reduction of the HDL values when compared 
to the control group.(p=0.00).  
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This was in consonant with  a study byVarun Chawla,et al34 
there was a significant inverse association between HDL-C and kidney 
failure. 
 
This is because ,HDL maturation is impaired in CKD through 
decreased activity of lecithin:cholesterol acyltransferase (LCAT), and 
increased cholesterol ester transfer protein (CETP) activity in MS 
shuttles triglycerides back into HDL, thereby destabilizing it. Low 
HDL cholesterol levels is a prominent feature of insulin resistance 
syndrome. 
 In our study HDL cholesterol was found to decrease in cases of 
IGT. 
 
TOTAL CHOLESTEROL AND IGT 
In our study 53.8% of patients with serum cholesterol >250 had IGT, 
whereas only 31% of the patients <250 had IGT. 
 
TRIGLYCERIDES AND IGT 
In our study in patients with TGL >250, 57% of CKD patients 
had IGT, when compared 32.5% patients with IGT with TGL <250. 
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SEX AND IGT 
 There was no significant difference in glucose tolerance between 
the sexes. 
BMI AND IGT 
The comparison between  body mass index and  IGT showed 
that , most of the patients fell in the normal BMI category and among 
them, 31.3% had IGT.  In the ill nourished with BMI less  than 18.5,5 
patients among the 14 in the group had IGT(35.7%). In the group with 
a BMI  between 24.9  to 30 , 5 of the 14 people had IGT i.e 35.7%. In 
the obese individuals with a BMI more than 30 ,1 of the only 2 patients 
had IGT. 
BMI correlates well with insulin resistance in general. This has 
been proved in various clinical and research studies. 
On the contrary most of our CKD patients present with normal 
BMI even though IGT was documented. This IGT is mainly due to 
uremic toxins, hyperparathyroidism etc. 
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SUMMARY 
This study titled a study of glucose tolerance in non diabetic CKD 
patients was conducted at the Govt Rajaji Hospital Madurai, between 
June and December 2010. The study was conducted on 90 non diabetic 
CKD patients after fulfilling the inclusion and exclusion criterias. An 
age and sex matched control group was also taken, consisting of 50 
people. A relevant meticulous history was obtained ,with relevant 
examinations and thereafter they were subjected to a battery of 
investigations, most importantly a 2 hour GTT, with one hour value 
too, along with the renal parameters  and fasting lipid profile.  
 
From the study the following observations were made, which were 
consistent with various national and international studies. 
 
1) Most CKD patients are in the age group of 31-40 and 51-60, 
showing a younger age group CKD unlike the western 
population, which could be attributed to the more frequent 
streptococcal infections. 
2) There was not much of difference in the sex distribution in this 
study, it showed only a  slight male preponderance which is 
consistent with various studies across communities. 
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3)  Among the patients in this study,most of them  belonged to 
stage 5 CKD (36%),  followed by stage 4,3 CKD, probably 
because patients fail to seek medical attention at an earlier time. 
4) IGT is more prevalent in stage 4 and 5 CKD. It was 48.4% in 
stage 5 CKD and 41.9% in stage 4 CKD. The predominant 
factor responsible for this was increased insulin  resistance, and 
reduced insulin sensitivity, in CKD patients.  
5) IGT can be taken as a marker of severity of renal failure like 
GFR.  
6) One hour post glucose load was also more in higher stages of 
CKD . 60.5% of patients with stage 5 CKD had impaired one 
hour glucose intolerance. Individuals with one hour impaired 
glucose more than 155 have a worse  cardiometabolic profile 
,and these patients have ,also have worsening insulin 
insensitivity. These patients could benefit from lifestyle changes, 
interventions and, possibly, pharmacotherapy to prevent or delay 
clinically adverse outcomes. 
7) The HDL-Cholesterol was found to be significantly lower in 
CKD patients when compared to the control group. This was as 
suggested by performing an independent variable T-test. The 
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mean HDL cholesterol was 41.61 in the study group compared 
to  46.8 in the control group.(p=0.00) 
8) The BMI in this study didn’t show any correlation with IGT. 
Most of the patients fell into the normal BMI group.  
9) BMI does not help to identify patients with IGT in CKD 
population. 
10) Most of our patients are malnourished and have normal or 
low BMI. 
11) Severity of proteinuria correlates with abnormal glucose 
metabolism, and may predict progression of renal failure. 
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CONCLUSION 
 
CKD is fast becoming a hidden epidemic as termed by madhumati rao 
et al39, and true to the fact it is fast becoming a major cause of 
mortality in the Indian scenario. 
 
Chronic kidney disease (CKD) has become one of the most important, 
chronic, noncommunicable disease epidemics in the world, including 
India. It is clear that treatment of CKD and its advanced stage, that is, 
end-stage renal disease (ESRD), is consuming a huge proportion of 
health resources in most of the country, and in India it is beyond the 
reach of the average Indian. Thus, it is crucial that prevention of CKD 
becomes an important goal of the medical fraternity, government, and 
public at large in any country, including India. 
 
In conclusion there is a high prevalence of IGT in the non- diabetic 
CKD patients, as the disease advances apart from a range of other 
metabolic parameters. The IGT is mainly contributed by the increasing 
Insulin resistance and decreased insulin sensitivity in CKD patients. 
Indeed, it has been postulated that the excess cardiovascular mortality 
that heralds and then subsequently accompanies the development of 
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kidney failure may have at least part of its origins in the insulin 
resistance that develops. 
The  one hour post glucose load impaired glucose tolerance was also 
higher, as the renal function worsens. The one hour IGT may act as a 
better predictor of adverse cardiovascular outcome, henceforth its 
imperative that we screen all CKD patients with an OGTT. These 
patients with IGT may benefit from lifestyle modifications  and 
possibly pharmacotherapy to prevent or to delay adverse outcomes. 
Various lipid abnormalities also occur in the setting of CKD , the most 
noted being a significant reduction in the HDL-cholesterol fraction, 
which is in addition an important co-efficient of metabolic syndrome, 
and further adverse outcome. 
 
Glucose tolerance also becomes impaired with worsening of 
proteinuria. Hence it is worthwhile in screening all patients with urine 
spot PCR , or microalbuminuria ,to catch the disease early, and thereby 
giving our patients a better outcome in life as well as a healthy one. 
Measures like adding ACE inhibitors or ARB’s may be started early in 
the disease so as to delay the progression of CKD. 
 ABBREVIATIONS 
 
ACE   Angiotensin Converting Enzyme 
ARB   Angiotensin Receptor blockers 
ATP                 Adenosine Tri Phosphate 
BMI   Body Mass Index 
BP   Blood pressure 
BUN                  Blood urea nitrogen  
CG    Cockroft Gault equation 
CHF   Congestive Heart Failure 
CKD                  Chronic kidney disease  
CRF                    Chronic renal failure 
 CRP   C- reactive Protein 
CVD                  Cardiovascular disease  
DM   Diabetes Mellitis 
EPO                 Erythropoietin 
ESR   Erythrocyte Sedimentation Ratio 
ESRD                 End stage renal disease 
FCR                 Fractional catabolic rate  
GFR                   Glomerular filtration rate 
 HbA1c   Glycosylated Hb 
HDL-C              High density lipoprotein Cholesterol 
 HKD   Hypertensive kidney disease 
HOMA-IR       Homeostasis model assessment of insulin resistance  
IFG   Impaired Fasting Glucose 
 IGF-1   Insulin Like Growth Factor 1 
IGT   Impaired glucose tolerance 
IP    Inpatients   
IR                       Insulin resistance 
KDOQI National Kidney Foundation Kidney Disease Quality 
Outcomes    Initiative  
LCAT              Lecithin:cholesterol acyltransferase  
LDL-C            Low density Lipoprotein Cholesterol 
MDRD             Modification of Diet in Renal Disease 
MS                   Metabolic syndrome  
NGT   Normal Glucose tolerance 
NHANES    National Health and Nutrition Examination Survey 
 NHDL-C     Non HDL Cholesterol 
NSAID   Non steroidal anti inflammatory drugs 
O-GlcNAc         N-acetylglucosamine 
OGTT   Oral Glucose tolerance Test 
OP   Out patients 
PCR   Protein Creatinine Ratio 
PDM   Pre Diabetes 
PG   Post glucose 
PTH                   Parathyroid hormone 
ROS                   Reactive oxygen species 
TG   Triglycerides 
UTI   Urinary Tract Infections 
WHO   World Health Organisation 
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FIGURE: 3 AGE DISTRIBUTION IN  CASES  AND CONTROLS 
 
 
 
FIGURE : 4  SEX DISTRIBUTION IN CASES AND CONTROLS 
 
 
 
 
  
 
 
FIGURE:5     IGT ON 2 HR GTT TO STAGE OF CKD 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE 6:  ONE HOUR POST –GLUCOSE LOAD  TO CKD STAGE 
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FIGURE 8 
 
relation between serum triglycerides & glucose tolerance
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FIGURE 10 
 
relation of body mass index and GTT
14
60
14
25
19
5 1
0
20
40
60
80
BMI
Fr
eq
ue
nc
total 
igtt
total 14 60 14 2
igtt 5 19 5 1
<18.5 18.5 - 24.9 24.9 - 29.9 >30
 
 
 
 
 
 
 
 
 
 
FIGURE 11 : ALBUMINURIA AND IGT. 
 
 
 
FIGURE 12 
 
 
 
  
 
 
 
FIGURE : 13 
 
 
 
 
 
 
 
 
  
 
 
 
FIGURE 14 
 
BIBLIOGRAPHY 
 
1. Harrison’s Principles of Internal Medicine 17th edition; 
2. Brenner and Rector’s The KIDNEY 8th edition; 
3. Davidson’s principles and practice of medicine21st edition 
4. dharan et al , Spectrum of severe chronic kidney disease in India: a 
clinicopathological study, Natl Med J India. 2006 Sep-
Oct;19(5):250-2 
5. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: 
Evaluation, classification and stratification. Am J Kidney Dis 
39:suppl 1, 2002. ). 
6. Mani MK. Experience with a program for prevention of chronic 
renal failure in India. Kidney Int 2003; 94 (Suppl) : S75-8. 
7. Agarwal SKet al, Prevalence of chronic renal failure in adults in 
Delhi, India. Nephrol Dial Transplant 2005; 20 : 1638-42. 
8. Excerpts from the United States Rental Data Systems 2002 annual 
report: Atlas of end-stage rental disease in the United States. Am J 
Kidney Dis 2003; 41 (4 Suppl 2) : v-ix, S7-254.  
9. Modi GK, Jha V. The incidence of end-stage renal disease in India: 
a population-based study. Kidney Int 2006; 70 : 2131-3. 
10. Corry DB, Tuck ML: Selective aspects of the insulin resistance 
syndrome.  Curr Opin Nephrol Hypertens  2001; 10(4):507-514.) 
11. ] Defronzo RA, Tobin JD, Rowe JW, Andres R: Glucose 
intolerance in uremia: Quantification of pancreatic beta cell 
sensitivity to glucose and tissue sensitivity to insulin.  J Clin 
Invest  1978; 62(2):425-435.  
12. Horton ES, Johnson C, Lebovitz HE: Carbohydrate metabolism in 
uremia.  Ann Intern Med  1968; 68(1):63-74.  
13. Spitz IM, Rubenstein AH, Bersohn I, et al: Carbohydrate 
metabolism in renal disease.  Q J Med  1970; 39(154):201-226 
14. Sit D, Kadiroglu AK, Yilmaz ME, et al: The prevalence of insulin 
resistance and its relationship between anemia, secondary 
hyperparathyroidism, inflammation, and cardiacparameters in 
chronic hemodialysis patients.  Ren Fail  2005; 27(4):403-407. 
15. Zoccali C, Tripepi G, Cambareri F, et al: Adipose tissue cytokines, 
insulin sensitivity, inflammation, and cardiovascular outcomes in 
end-stage renal disease patients.  J Ren Nutr  2005; 15(1):125-130.  
16. Lee SW, Park GH, Lee SW, et al: Insulin resistance and muscle 
wasting in non-diabetic end-stage renal disease patients. Nephrol 
Dial Transplant 2007. 
17. Allegra V, Mengozzi G, Martimbianco L, Vasile A: Glucose-
induced insulin secretion in uremia: Effects of aminophylline 
infusion and glucose loads.  Kidney Int  1990; 38(6):1146-1150. 
18. Fishman S, Rapoport MJ, Weissgarten J, et al: The effect of 
Losartan on insulin resistance and beta cell function in chronic 
hemodialysis patients.  Ren Fail  2001; 23(5):685-692. 
19. Fliser D, Kielstein JT, Menne J: Insulin resistance and renal 
disease.  Contrib Nephrol  2006; 151:203-211. 
20. Sarafidis PA, Ruilope LM: Insulin resistance, hyperinsulinemia, 
and renal injury: Mechanisms and implications.  Am J 
Nephrol  2006; 26(3):232-244. 
21. API TEXTBOOK OF MEDICINE 8th edition ,2008,vol1,737 
22. Nigeria study;Journal of renal nutrition volume 17 Issue 1 january 
2007; 
23. Journal of clinical investigation volume 120 Issue 1 , 2010 ; 
24. CHADBAN, S, BRIGANTI, E, KERR, P, et al: Prevalence of 
kidney damage in Australian adults: The AusDiab Kidney Study. J 
Am Soc Nephrol 2003 14:S131–S138; 
25. ATKINS et al Kidney International (2005) 67, S14–S18;  
26. Mads Hornum et al,Pre-diabetes and arterial stiffness in uraemic 
patientsNephrol. Dial. Transplant. (2010) 25(4): 1218-1225  
27. Walid Shehab-Eldin et al , American journal of nephrology 
2009;29:406-413 
28. Kobayashi S et al ,American Journal of Kidney Disease. 2005 
Aug;46(2):367   
29. Fadi A. El-Atat et al, JASN Nov 1, 2004 15: 2816-2827 
30. Insulin Resistance and Risk of Chronic Kidney Disease in 
Nondiabetic US AdultsJASN February 1, 2003 14): (2) 469-477; 
31. Elena Succurro et al,One-Hour Post load Plasma Glucose Levels 
Are Associated with Kidney DysfunctionCJASN November 
2010 5): (11) 1922-1927; 
32. Masao Kanauchi et al, Insulin resistance and pancreatic beta-cell 
function in patients with hypertensive kidney diseaseNephrol. Dial. 
Transplant. (2004) 19(8): 2025-2029  
33. Comparison of glucose tolerance in renal transplant recipients and 
hemodialysis patients,BMC NEPHROLOGY,2004,Volume 5, 
Number 1, 1-5, 10.1186/1471-2369-5-11 
34. Varun Chawla, Dr. Vandana Menon et al , Hyperlipidemia and 
Long-Term Outcomes in Nondiabetic Chronic Kidney 
Disease,CJASN September 2010vol. 5 no. 9 1582-1587 
35. Donald S. Silverberg et al, The effect of correction of anaemia in 
diabetics and non‐diabetics with severe resistant congestive heart 
failure and chronic renal failure by subcutaneous erythropoietin and 
intravenous iron,Nephrol. Dial. Transplant. (2003)18 (1): 141-146. 
36. World Health Organization and International Diabetes Federation 
(1999). Definition, diagnosis and classification of diabetes mellitus 
and its complications. Geneva, Switzerland: World Health 
Organization. 
37. SPSS SOFTWARE version 17.0 
38. Rao et al,Haemodialysis for end-stage renal disease in Southern 
India--a perspective from a tertiary referral care centre 
39. Nephrol. Dial. Transplant. (1998)13 (10): 2494-2500. 
40. ,. madhumathi et al,hemodialysis for end stage renal disease in 
southern india, Nephrol. Dial. Transplant. (1998)13 (10): 2494-
2500. 
41. GIUSEPPE REMUZZI ET AL, Kidney International (2004) 66, S90–
S96; 
42. Edward Kessle et alr, Proteinuria and mild glucose 
intolerance”2,the American Journal of Clinical Nutrition 24: 
APRIL 1971, pp. 475-479.Alessia Fornoni et al, .N Engl J Med 
2010; 363:2068-2069 
 
